Harmony Biosciences Holdings (HRMY) Change in Receivables (2020 - 2026)

Harmony Biosciences Holdings (HRMY) has 7 years of Change in Receivables data on file, last reported at $11.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 50.14% year-over-year to $11.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 91.42% YoY), and the FY2025 full-year result was $13.8 million, up 54.66% from the prior year.
• Change in Receivables improved to $11.4 million in Q1 2026, from -$3.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $22.9 million in Q1 2025 to a low of -$13.0 million in Q2 2025.
• A 5-year average of $4.3 million and a median of $3.5 million in 2023 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables soared 2215.69% in 2023 and slumped 477.78% in 2025, its largest moves.
• Tracing HRMY's Change in Receivables over 5 years: stood at -$325000.0 in 2022, then soared by 2215.69% to $6.9 million in 2023, then tumbled by 77.73% to $1.5 million in 2024, then plunged by 352.38% to -$3.9 million in 2025, then soared by 395.94% to $11.4 million in 2026.
• Business Quant data shows HRMY's Change in Receivables at $11.4 million in Q1 2026, -$3.9 million in Q4 2025, and $7.7 million in Q3 2025.